

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT


SUGEMALIMAB RECEIVES [I, A] RECOMMENDATION IN ESMO GUIDELINE FOR CONSOLIDATION THERAPY IN PATIENTS WITH STAGE III NSCLC

This announcement is made by CStone Pharmaceuticals (the “Company,” together with its subsidiaries, collectively referred to as the “Group” or “CStone”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

.....

CStone today announced that its core commercial product, sugemalimab, has received a [I, A] recommendation in the *European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline*. This recommendation support sugemalimab for consolidation therapy in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed after concurrent or sequential chemoradiotherapy. This recommendation is expected to significantly facilitate market access for sugemalimab in the European Union and other regions, expanding patient reach – thus strengthening its global commercialization.

In February 2025, sugemalimab in combination with chemotherapy had received a [I, A] recommendation from the ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline for the first-line treatment of both squamous and non-squamous metastatic (Stage IV) NSCLC. To date, both NSCLC indications for which sugemalimab is approved in the EU and UK are now included in ESMO guidelines, underscoring its recognized clinical value.



Guideline reference: <https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-early-and-locally-advanced-nsclc/management-of-early-and-locally-advanced-nsclc/management-of-unresectable-stage-iii-nsclc/therapy-for-unresectable-stage-iii-nsclc>

As per the latest ESMO guideline update:

Sugemalimab consolidation therapy is recommended for patients with EGFR wild-type and no ALK or ROS1 genomic tumour aberrations, stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy, for a duration of up to 24 months. This [I, A] recommendation applies to patients whose tumors express PD-L1 on $\geq 1\%$ of tumor cells (TC) [ESMO-MCBS v2.0 score: 3; approved by European Medicines Agency (EMA)].

This recommendation is based on the results from the pivotal Phase III GEMSTONE-301 clinical trial, which demonstrated that sugemalimab provided a statistically significant improvement in progression-free survival (PFS) and a clinically meaningful extension in overall survival (OS) for patients with Stage III NSCLC.

To date, sugemalimab has secured four commercialization partnerships across Europe, the Middle East and Africa, and Latin America, covering more than 60 countries and regions. Market access applications have been approved or are under review in more than ten countries, as the product's international commercialization continues to advance actively.

About Sugemalimab

The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat[®] transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.

The European Commission (EC) and Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab for two indications:

- In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations; and
- Monotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on $\geq 1\%$ of tumor cells and no sensitising EGFR mutations, or ALK, ROS1 genomic aberrations and whose

disease has not progressed following platinum-based CRT.

The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:

- In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and metastatic squamous NSCLC;
- For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based CRT;
- For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;
- In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and
- In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression CPS ≥ 5 .

ESMO Guidelines recommend sugemalimab [I, A] for:

- In combination with platinum-doublet chemotherapy as first-line treatment for non-oncogene-addicted stage IV patients with squamous NSCLC, performance status (PS) 0-1, regardless of tumor PD-L1 status and without contraindications for immune checkpoint inhibitors (ICI);
- In combination with platinum-based chemotherapy as first-line treatment for non-oncogene-addicted stage IV patients with non-squamous NSCLC, PS 0-1, regardless of tumor PD-L1 status and without contraindications for ICI; and
- Consolidation therapy for up to 24 months in patients with stage III NSCLC who are EGFR wild-type and lack ALK or ROS1 genomic aberrations, following concurrent or sequential chemoradiotherapy without disease progression.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The Company's pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: THE COMPANY CANNOT GUARANTEE THAT WE MAY BE ABLE TO ULTIMATELY DEVELOP AND MARKET SUGEMALIMAB SUCCESSFULLY. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, March 25, 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.